Article
Inhibition or activation of Apert syndrome FGFR2 (S252W) signaling by specific glycosaminoglycans.
The Journal of biological chemistry - 17 Mar 2006
McDowell Lynda M, Frazier Beth A, Studelska Daniel R, Giljum Kari, Chen Jinghua, Liu Jian, Yu Kai, Ornitz David M, Zhang Lijuan
Abstract excerpt
Most Apert syndrome patients harbor a single amino acid mutation (S252W) in fibroblast growth factor (FGF) receptor 2 (FGFR2), which leads to abnormal FGF/FGFR2 signaling. Here we show that specific combinations of FGFs and glycosaminoglycans activate both alternative splice forms of the mutant but not of the wild-type FGF receptors. More importantly, 2-O- and N-sulfated heparan sulfate, prepared by a combined...
Topics
- Acrocephalosyndactylia
- Animals
- Cartilage
- Cattle
- Cell Line
- Cell Proliferation
- Chromatography, High Pressure Liquid
- Decapodiformes
- Dose-Response Relationship, Drug
- Fibroblast Growth Factors
- Glycosaminoglycans
- Heparin
- Humans